Main Topic Lens: Updates from the 2025 San Antonio Breast Cancer Symposium. 2025 San Antonio Breast Cancer Symposium Highlight Recap Dana-Farber Cancer Institute.

2025 San Antonio Breast Cancer Symposium Highlight Recap Dana Farber Cancer Institute - Guide Reference Overview

This page organizes 2025 San Antonio Breast Cancer Symposium Highlight Recap Dana Farber Cancer Institute with important details, common questions, and next-step references in a simple and scannable format.

Harold Burstein, MD, PhD, summarizes important breakthroughs presented at the 2025 San Antonio Breast Cancer Symposium. 2025 San Antonio Breast Cancer Symposium Highlights Dana-Farber Cancer Institute.

Guide Reference Overview

Harold Burstein, MD, PhD, and Sarah Sammons, MD, discuss the DESTINYBreast09, HER2-CLIMB, and PATINA CNS trials for ... 2025 SABCS Highlights: Advances in ctDNA for Breast Cancer Dana-Farber Cancer Institute.

Guide Why It Matters

ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05 Dana-Farber Cancer Institute. Hal Burstein, MD, PhD, shared the latest updates on treatment and research breakthroughs for metastatic breast cancer from the ... 2025 San Antonio Breast Cancer Symposium Update 2025-2026 EMBRACE MBC Virtual Forum Series.

Context What to Know

2025 San Antonio Breast Cancer Symposium Update 2025-2026 EMBRACE MBC Virtual Forum Series. 2025 SABCS Highlights: Targeted Therapies for Advanced Breast Cancer Dana-Farber Cancer Institute.

Context Before You Decide

Lindsay Northrop, breast cancer survivor and patient advocate at Dana-Farber, talks with Harold Burstein, MD, PhD, about how ... Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss important advances in ctDNA and minimal residual disease ... Harold Burstein, MD, PhD, and Guilherme Nader Marta, MD, discuss the DESTINY-Breast11 and DESTINY-Breast05 trials ...

Main details to review

  • 2025 SABCS Highlights: First-Line Tx for HER2+ Advanced Breast Cancer Dana-Farber Cancer Institute.
  • SABCS 2025 Breast Cancer Highlights Panel Discussion Dana-Farber Cancer Institute.
  • Lindsay Northrop, breast cancer survivor and patient advocate at Dana-Farber, talks with Harold Burstein, MD, PhD, about how ...
  • Hal Burstein, MD, PhD, shared the latest updates on treatment and research breakthroughs for metastatic breast cancer from the ...

How this reference can help

This page is useful when readers need clear context before opening more detailed pages.

Sponsored

Reader Questions

How should beginners approach 2025 San Antonio Breast Cancer Symposium Highlight Recap Dana Farber Cancer Institute?

Beginners should scan the overview first, then use related terms to narrow the subject into a more specific question.

What questions should readers ask about 2025 San Antonio Breast Cancer Symposium Highlight Recap Dana Farber Cancer Institute?

Check freshness, source quality, related examples, and any requirements or limitations before relying on one answer.

What should be checked first?

Readers should check the main context, important requirements, source freshness, and any details that may change over time.

Visual Discovery Notes

2025 San Antonio Breast Cancer Symposium Highlight Recap | Dana-Farber Cancer Institute
SABCS 2025 Breast Cancer Highlights Panel Discussion | Dana-Farber Cancer Institute
2025 San Antonio Breast Cancer Symposium Highlights | Dana-Farber Cancer Institute
2025 SABCS Highlights: Targeted Therapies for Advanced Breast Cancer | Dana-Farber Cancer Institute
2025 SABCS Highlights: Advances in ctDNA for Breast Cancer | Dana-Farber Cancer Institute
2025 San Antonio Breast Cancer Symposium Update | 2025-2026 EMBRACE MBC Virtual Forum Series
2025 SABCS Highlights: First-Line Tx for HER2+ Advanced Breast Cancer | Dana-Farber Cancer Institute
2025 SABCS Highlights: Patient Perspective | Dana-Farber Cancer Institute
Updates from the 2025 San Antonio Breast Cancer Symposium
2025 SABCS Highlights: Hormone Replacement Therapy for Breast Cancer | Dana-Farber Cancer Institute
2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast
ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05 | Dana-Farber Cancer Institute
Sponsored
See Related Details
2025 San Antonio Breast Cancer Symposium Highlight Recap | Dana-Farber Cancer Institute

2025 San Antonio Breast Cancer Symposium Highlight Recap | Dana-Farber Cancer Institute

Harold Burstein, MD, PhD, summarizes important breakthroughs presented at the 2025 San Antonio Breast Cancer Symposium.

SABCS 2025 Breast Cancer Highlights Panel Discussion | Dana-Farber Cancer Institute

SABCS 2025 Breast Cancer Highlights Panel Discussion | Dana-Farber Cancer Institute

Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Sarah Sammons, MD; Ana C. Garrido-Castro, MD; and ...

2025 San Antonio Breast Cancer Symposium Highlights | Dana-Farber Cancer Institute

2025 San Antonio Breast Cancer Symposium Highlights | Dana-Farber Cancer Institute

Harold Burstein, MD, PhD, and other breast cancer experts at Dana-Farber discuss important breast cancer research presented at ...

2025 SABCS Highlights: Targeted Therapies for Advanced Breast Cancer | Dana-Farber Cancer Institute

2025 SABCS Highlights: Targeted Therapies for Advanced Breast Cancer | Dana-Farber Cancer Institute

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the CAPItello-291, VIKTORIA-1, and STX-478 trials which were ...

2025 SABCS Highlights: Advances in ctDNA for Breast Cancer | Dana-Farber Cancer Institute

2025 SABCS Highlights: Advances in ctDNA for Breast Cancer | Dana-Farber Cancer Institute

Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss important advances in ctDNA and minimal residual disease ...

2025 San Antonio Breast Cancer Symposium Update | 2025-2026 EMBRACE MBC Virtual Forum Series

2025 San Antonio Breast Cancer Symposium Update | 2025-2026 EMBRACE MBC Virtual Forum Series

Hal Burstein, MD, PhD, shared the latest updates on treatment and research breakthroughs for metastatic breast cancer from the ...

2025 SABCS Highlights: First-Line Tx for HER2+ Advanced Breast Cancer | Dana-Farber Cancer Institute

2025 SABCS Highlights: First-Line Tx for HER2+ Advanced Breast Cancer | Dana-Farber Cancer Institute

Harold Burstein, MD, PhD, and Sarah Sammons, MD, discuss the DESTINYBreast09, HER2-CLIMB, and PATINA CNS trials for ...

2025 SABCS Highlights: Patient Perspective | Dana-Farber Cancer Institute

2025 SABCS Highlights: Patient Perspective | Dana-Farber Cancer Institute

Lindsay Northrop, breast cancer survivor and patient advocate at Dana-Farber, talks with Harold Burstein, MD, PhD, about how ...

Updates from the 2025 San Antonio Breast Cancer Symposium

Updates from the 2025 San Antonio Breast Cancer Symposium

Each year, the San Antonio Breast Cancer Symposium (SABCS) brings together thousands of clinicians, researchers, and ...

2025 SABCS Highlights: Hormone Replacement Therapy for Breast Cancer | Dana-Farber Cancer Institute

2025 SABCS Highlights: Hormone Replacement Therapy for Breast Cancer | Dana-Farber Cancer Institute

Harold Burstein, MD, PhD, and Wendy Y. Chen, MD, MPH, discuss research in hormone replacement therapy for breast cancer ...

2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast

2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast

Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc, about new clinical trial data and updates ...

ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05 | Dana-Farber Cancer Institute

ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05 | Dana-Farber Cancer Institute

Harold Burstein, MD, PhD, and Guilherme Nader Marta, MD, discuss the DESTINY-Breast11 and DESTINY-Breast05 trials ...